Cohort Studymoderate evidence
Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.
The Annals of pharmacotherapy·July 5, 2026·PMID 42402098
Why it mattersCritically ill patients with AKI often have altered pharmacokinetics, and standard renal dose adjustments may lead to subtherapeutic antibiotic levels, potentially worsening outcomes. This study challenges the common practice of immediate dose reduction for piperacillin/tazobactam in early AKI.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled